Mira Pharmaceuticals

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.